BG104151A - 3-ЗАМЕСТЕНИ 3,4,5,7-ТЕТРАХИДРОПИРОЛО [3,4,:4,5] ТИЕНО [2,39г] ПИРИМИДИНОВИ ПРОИЗВОДНИ, ТЯХНОТО ПОЛУЧАВАНЕ И ИЗПОЛЗВАНЕ - Google Patents
3-ЗАМЕСТЕНИ 3,4,5,7-ТЕТРАХИДРОПИРОЛО [3,4,:4,5] ТИЕНО [2,39г] ПИРИМИДИНОВИ ПРОИЗВОДНИ, ТЯХНОТО ПОЛУЧАВАНЕ И ИЗПОЛЗВАНЕ Download PDFInfo
- Publication number
- BG104151A BG104151A BG104151A BG10415100A BG104151A BG 104151 A BG104151 A BG 104151A BG 104151 A BG104151 A BG 104151A BG 10415100 A BG10415100 A BG 10415100A BG 104151 A BG104151 A BG 104151A
- Authority
- BG
- Bulgaria
- Prior art keywords
- thieno
- ethyl
- tetrahydro
- pyrrolo
- pyrimidin
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract description 5
- DDWBRNXDKNIQDY-UHFFFAOYSA-N thieno[2,3-d]pyrimidine Chemical class N1=CN=C2SC=CC2=C1 DDWBRNXDKNIQDY-UHFFFAOYSA-N 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 claims abstract description 5
- 150000003230 pyrimidines Chemical class 0.000 claims abstract description 4
- -1 C 1 -C 4 alkyl Chemical group 0.000 claims description 57
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 40
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 20
- 229940076279 serotonin Drugs 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 208000020401 Depressive disease Diseases 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 230000000697 serotonin reuptake Effects 0.000 claims description 2
- 230000008485 antagonism Effects 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 38
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 239000012043 crude product Substances 0.000 description 7
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 102000007527 Autoreceptors Human genes 0.000 description 6
- 108010071131 Autoreceptors Proteins 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000003518 presynaptic effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- UHFQDUNSYUAETO-UHFFFAOYSA-N 7-thia-4,9,11-triazatricyclo[6.4.0.02,6]dodeca-1,3,5,8,10-pentaen-12-one Chemical compound N=1C=NC(C=2C=1SC=1C=2C=NC=1)=O UHFQDUNSYUAETO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- JEDVKUHCDPPWNR-UHFFFAOYSA-N 3h-thieno[2,3-d]pyrimidin-4-one Chemical compound O=C1NC=NC2=C1C=CS2 JEDVKUHCDPPWNR-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- IQMMWXZJVYDFIC-UHFFFAOYSA-N diethyl 2-amino-4,6-dihydrothieno[2,3-c]pyrrole-3,5-dicarboxylate Chemical compound S1C(N)=C(C(=O)OCC)C2=C1CN(C(=O)OCC)C2 IQMMWXZJVYDFIC-UHFFFAOYSA-N 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 230000000862 serotonergic effect Effects 0.000 description 2
- 239000004000 serotonin 1B antagonist Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VNICFCQJUVFULD-UHFFFAOYSA-N 1-(1-naphthalenyl)piperazine Chemical compound C1CNCCN1C1=CC=CC2=CC=CC=C12 VNICFCQJUVFULD-UHFFFAOYSA-N 0.000 description 1
- YWWZASFPWWPUBN-UHFFFAOYSA-N 1-bromoisoquinoline Chemical compound C1=CC=C2C(Br)=NC=CC2=C1 YWWZASFPWWPUBN-UHFFFAOYSA-N 0.000 description 1
- DLKQHBOKULLWDQ-UHFFFAOYSA-N 1-bromonaphthalene Chemical compound C1=CC=C2C(Br)=CC=CC2=C1 DLKQHBOKULLWDQ-UHFFFAOYSA-N 0.000 description 1
- YCWRFIYBUQBHJI-UHFFFAOYSA-N 2-(4-aminophenyl)acetonitrile Chemical group NC1=CC=C(CC#N)C=C1 YCWRFIYBUQBHJI-UHFFFAOYSA-N 0.000 description 1
- NDVVQPVEUGLAPX-UHFFFAOYSA-N 2-[4-(2-methoxyphenyl)piperazin-1-yl]ethanamine Chemical compound COC1=CC=CC=C1N1CCN(CCN)CC1 NDVVQPVEUGLAPX-UHFFFAOYSA-N 0.000 description 1
- XBSNSJDXWAOVIY-UHFFFAOYSA-N 2-[4-[2-(2-methyl-8-oxo-1,3-dihydropyrrolo[2,3]thieno[2,4-d]pyrimidin-7-yl)ethyl]piperazin-1-yl]benzonitrile Chemical compound O=C1C=2C=3CN(C)CC=3SC=2N=CN1CCN(CC1)CCN1C1=CC=CC=C1C#N XBSNSJDXWAOVIY-UHFFFAOYSA-N 0.000 description 1
- QXTJKRFNIVUWGW-UHFFFAOYSA-N 2-acetyl-7-[2-[4-(2-methylnaphthalen-1-yl)piperazin-1-yl]ethyl]-1,3-dihydropyrrolo[2,3]thieno[2,4-d]pyrimidin-8-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCN3C=NC=4SC=5CN(CC=5C=4C3=O)C(=O)C)=C(C)C=CC2=C1 QXTJKRFNIVUWGW-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- JMBLSGAXSMOKPN-UHFFFAOYSA-N 2-methylnaphthalen-1-amine Chemical compound C1=CC=CC2=C(N)C(C)=CC=C21 JMBLSGAXSMOKPN-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NIBZKHUIJGTBOX-UHFFFAOYSA-N 4-piperazin-1-ylisoquinoline Chemical compound C1CNCCN1C1=CN=CC2=CC=CC=C12 NIBZKHUIJGTBOX-UHFFFAOYSA-N 0.000 description 1
- 102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 description 1
- 101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- LQIXLZRAOIOECZ-UHFFFAOYSA-N 7-[2-[4-(2,3-dimethylphenyl)piperazin-1-yl]ethyl]-2-ethyl-1,3-dihydropyrrolo[2,3]thieno[2,4-d]pyrimidin-8-one Chemical compound O=C1C=2C=3CN(CC)CC=3SC=2N=CN1CCN(CC1)CCN1C1=CC=CC(C)=C1C LQIXLZRAOIOECZ-UHFFFAOYSA-N 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- NFGDUAZCBSIDMB-UHFFFAOYSA-N CCOC(=O)C1=C(SC2=C1CNC2)C(=O)OCC Chemical compound CCOC(=O)C1=C(SC2=C1CNC2)C(=O)OCC NFGDUAZCBSIDMB-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 102000004659 Presynaptic Receptors Human genes 0.000 description 1
- 108010003717 Presynaptic Receptors Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010042209 Stress Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000001908 autoinhibitory effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- TXFLGZOGNOOEFZ-UHFFFAOYSA-N bis(2-chloroethyl)amine Chemical compound ClCCNCCCl TXFLGZOGNOOEFZ-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004802 cyanophenyl group Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- UXBDIUBADZDARJ-UHFFFAOYSA-N ethyl 2-(ethoxymethylideneamino)-5-ethyl-6,7-dihydro-4h-thieno[3,2-c]pyridine-3-carboxylate Chemical compound C1CN(CC)CC2=C1SC(N=COCC)=C2C(=O)OCC UXBDIUBADZDARJ-UHFFFAOYSA-N 0.000 description 1
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
- XWNGDLOIWXIPGP-UHFFFAOYSA-N ethyl 7-[2-(4-naphthalen-1-ylpiperazin-1-yl)ethyl]-8-oxo-1,3-dihydropyrrolo[2,3]thieno[2,4-d]pyrimidine-2-carboxylate Chemical compound C1=CC=C2C(N3CCN(CC3)CCN3C=NC=4SC=5CN(CC=5C=4C3=O)C(=O)OCC)=CC=CC2=C1 XWNGDLOIWXIPGP-UHFFFAOYSA-N 0.000 description 1
- XUVVLBWUZCSVQW-UHFFFAOYSA-N ethyl 7-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-8-oxo-1,3-dihydropyrrolo[2,3]thieno[2,4-d]pyrimidine-2-carboxylate Chemical compound O=C1C=2C=3CN(C(=O)OCC)CC=3SC=2N=CN1CCN(CC1)CCN1C1=CC=CC=C1OC XUVVLBWUZCSVQW-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19734444A DE19734444A1 (de) | 1997-08-08 | 1997-08-08 | 3-Substituierte 3,4,5,7-Tetrahydro-pyrrolo(3',4':4,5) thieno (2,3-d) pyrimidin-Derivate, ihre Herstellung und Verwendung |
| PCT/EP1998/004633 WO1999007711A1 (de) | 1997-08-08 | 1998-07-23 | 3-substituierte 3,4,5,7-tetrahydro-pyrrolo[3',4':4,5] thieno[2,3-d] pyrimidin-derivate, ihre herstellung und verwendung als 5ht-antagonisten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG104151A true BG104151A (bg) | 2000-10-31 |
Family
ID=7838438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG104151A BG104151A (bg) | 1997-08-08 | 2000-02-10 | 3-ЗАМЕСТЕНИ 3,4,5,7-ТЕТРАХИДРОПИРОЛО [3,4,:4,5] ТИЕНО [2,39г] ПИРИМИДИНОВИ ПРОИЗВОДНИ, ТЯХНОТО ПОЛУЧАВАНЕ И ИЗПОЛЗВАНЕ |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6355647B1 (cs) |
| EP (1) | EP1003752A1 (cs) |
| JP (1) | JP2001512734A (cs) |
| KR (1) | KR20010022658A (cs) |
| CN (1) | CN1267303A (cs) |
| AR (1) | AR016594A1 (cs) |
| AU (1) | AU749539B2 (cs) |
| BG (1) | BG104151A (cs) |
| BR (1) | BR9811091A (cs) |
| CA (1) | CA2300391A1 (cs) |
| CO (1) | CO4960665A1 (cs) |
| CZ (1) | CZ290678B6 (cs) |
| DE (1) | DE19734444A1 (cs) |
| HR (1) | HRP980435A2 (cs) |
| HU (1) | HUP0101311A3 (cs) |
| ID (1) | ID24222A (cs) |
| IL (1) | IL134161A0 (cs) |
| NO (1) | NO20000605L (cs) |
| NZ (1) | NZ502657A (cs) |
| PL (1) | PL340726A1 (cs) |
| SK (1) | SK1052000A3 (cs) |
| TR (1) | TR200000371T2 (cs) |
| TW (1) | TW513435B (cs) |
| WO (1) | WO1999007711A1 (cs) |
| ZA (1) | ZA987114B (cs) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040048874A1 (en) * | 2001-05-22 | 2004-03-11 | Bardsley Hazel Judith | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine |
| GB0216027D0 (en) * | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
| DE10259382A1 (de) * | 2002-12-18 | 2004-07-01 | Abbott Gmbh & Co. Kg | 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-4-on-Derivate, ihre Herstellung und Verwendung |
| AU2004204825B2 (en) * | 2003-01-13 | 2007-07-19 | Dynogen Pharmaceuticals, Inc. | Method of treating functional bowel disorders |
| DE602004005814T2 (de) * | 2003-01-13 | 2008-01-10 | Dynogen Pharmaceuticals Inc., Waltham | Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus |
| US6846823B2 (en) * | 2003-04-04 | 2005-01-25 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
| US20050165025A1 (en) * | 2004-01-22 | 2005-07-28 | Recordati Ireland Ltd. | Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists |
| US7375814B2 (en) * | 2005-03-11 | 2008-05-20 | Sandia Corporation | Natural gas leak mapper |
| WO2006105117A2 (en) * | 2005-03-28 | 2006-10-05 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
| WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5001130A (en) | 1988-02-18 | 1991-03-19 | Bristol-Myers Company | Psychotropic heterobicycloalkylpiperazine derivatives |
| US4835157A (en) | 1988-03-15 | 1989-05-30 | Ortho Pharmaceutical Corporation | Thieno- and furopyrimidine-2,4-dione piperidine derivatives as serotonin antagonists and alpha adrenergic blocking agents |
| DE19636769A1 (de) | 1996-09-10 | 1998-03-12 | Basf Ag | 3-Substituierte Pyrido [4',3':4,5]thieno[2,3-d]pyrimidin-Derivate, ihre Herstellung und Verwendung |
-
1997
- 1997-08-08 DE DE19734444A patent/DE19734444A1/de not_active Withdrawn
-
1998
- 1998-07-23 EP EP98942610A patent/EP1003752A1/de not_active Withdrawn
- 1998-07-23 AU AU90683/98A patent/AU749539B2/en not_active Ceased
- 1998-07-23 NZ NZ502657A patent/NZ502657A/en unknown
- 1998-07-23 JP JP2000506214A patent/JP2001512734A/ja active Pending
- 1998-07-23 SK SK105-2000A patent/SK1052000A3/sk unknown
- 1998-07-23 IL IL13416198A patent/IL134161A0/xx unknown
- 1998-07-23 WO PCT/EP1998/004633 patent/WO1999007711A1/de not_active Application Discontinuation
- 1998-07-23 CA CA002300391A patent/CA2300391A1/en not_active Abandoned
- 1998-07-23 ID IDW20000239A patent/ID24222A/id unknown
- 1998-07-23 HU HU0101311A patent/HUP0101311A3/hu unknown
- 1998-07-23 PL PL98340726A patent/PL340726A1/xx not_active Application Discontinuation
- 1998-07-23 CZ CZ2000462A patent/CZ290678B6/cs not_active IP Right Cessation
- 1998-07-23 CN CN98808009A patent/CN1267303A/zh active Pending
- 1998-07-23 KR KR1020007001252A patent/KR20010022658A/ko not_active Withdrawn
- 1998-07-23 BR BR9811091-8A patent/BR9811091A/pt not_active IP Right Cessation
- 1998-07-23 TR TR2000/00371T patent/TR200000371T2/xx unknown
- 1998-07-23 US US09/485,188 patent/US6355647B1/en not_active Expired - Lifetime
- 1998-08-06 HR HR19734444.5A patent/HRP980435A2/hr not_active Application Discontinuation
- 1998-08-07 AR ARP980103914A patent/AR016594A1/es not_active Application Discontinuation
- 1998-08-07 TW TW087113048A patent/TW513435B/zh active
- 1998-08-07 ZA ZA9807114A patent/ZA987114B/xx unknown
- 1998-08-10 CO CO98045546A patent/CO4960665A1/es unknown
-
2000
- 2000-02-07 NO NO20000605A patent/NO20000605L/no not_active Application Discontinuation
- 2000-02-10 BG BG104151A patent/BG104151A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA987114B (en) | 2000-02-07 |
| CO4960665A1 (es) | 2000-09-25 |
| NO20000605D0 (no) | 2000-02-07 |
| BR9811091A (pt) | 2000-09-12 |
| TW513435B (en) | 2002-12-11 |
| US6355647B1 (en) | 2002-03-12 |
| SK1052000A3 (en) | 2000-08-14 |
| CA2300391A1 (en) | 1999-02-18 |
| JP2001512734A (ja) | 2001-08-28 |
| AU749539B2 (en) | 2002-06-27 |
| HUP0101311A1 (hu) | 2001-09-28 |
| DE19734444A1 (de) | 1999-02-11 |
| IL134161A0 (en) | 2001-04-30 |
| WO1999007711A1 (de) | 1999-02-18 |
| NZ502657A (en) | 2001-06-29 |
| CN1267303A (zh) | 2000-09-20 |
| AU9068398A (en) | 1999-03-01 |
| CZ2000462A3 (cs) | 2000-05-17 |
| TR200000371T2 (tr) | 2000-11-21 |
| PL340726A1 (en) | 2001-02-26 |
| AR016594A1 (es) | 2001-07-25 |
| ID24222A (id) | 2000-07-13 |
| HUP0101311A3 (en) | 2002-10-28 |
| HRP980435A2 (en) | 1999-04-30 |
| KR20010022658A (ko) | 2001-03-26 |
| CZ290678B6 (cs) | 2002-09-11 |
| NO20000605L (no) | 2000-02-07 |
| EP1003752A1 (de) | 2000-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6159962A (en) | 3-substituted 3,4-dihydro-thieno[2,3-D]pyrimidine derivatives and production and use of the same | |
| WO2007129111A1 (en) | Diazepine derivatives as 5-ht2a antagonists | |
| BG104151A (bg) | 3-ЗАМЕСТЕНИ 3,4,5,7-ТЕТРАХИДРОПИРОЛО [3,4,:4,5] ТИЕНО [2,39г] ПИРИМИДИНОВИ ПРОИЗВОДНИ, ТЯХНОТО ПОЛУЧАВАНЕ И ИЗПОЛЗВАНЕ | |
| US6159981A (en) | 3-substituted pyrido [3',4':4,5] Thieno [2,3-d] pyrimidine derivatives, and production and use of the same | |
| MXPA00001119A (en) | 3-substituted 3,4,5,7-tetrahydro-pyrrolo3',4':4,5 thieno2,3-dpyrimidine derivatives, their preparation and use as 5ht antagonists | |
| MXPA99010622A (en) | 3-substituted 3,4 dihydro-thieno[2, 3-d]pyrimidine derivatives and production and use of the same | |
| MXPA99010621A (en) | 3-substituted pyrido [3',4':4,5]thieno [2,3-d]pyrimidine derivatives, and production and use of the same | |
| SK286055B6 (sk) | Indenoindolónové zlúčeniny, spôsob ich prípravy afarmaceutické kompozície s ich obsahom | |
| CZ448399A3 (cs) | 3-substituované deriváty pyrido[3',4':4,5] thieno[2,3-d] pyrimidinu, jejich výroba a použití | |
| MXPA00003136A (en) | 2-substituted 1,2-benzisothiazole derivatives and their use as serotonin antagonists (5-ht1a, 5-ht1b and 5-ht1d) | |
| MXPA00002601A (en) | 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use |